Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 2/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11483813 | 0.85 | CYP11B1 (0.43) | CYP11B1ADRA2CCYP11B2BRD4ADORA2A | |
| SCHEMBL3130833 | 0.83 | ADORA2A (0.47) | CYP11B1CYP11B2ADORA2ASMN1; SMN2TDP1 | |
| SCHEMBL15432549 | 0.76 | CYP11B1 (0.40) | CYP11B1ADRA2CCYP11B2ADORA2ASMN1; SMN2 | |
| SCHEMBL4055988 | 0.73 | ADORA2A (0.41) | CYP11B1CYP11B2ADORA2AQPCTMAPK14 | |
| SCHEMBL22639937 | 0.73 | QPCT (0.50) | ADRA2CADORA2AQPCTQPCTLMEN1 | |
| SCHEMBL4639433 | 0.71 | SMN1; SMN2 (0.36) | QPCTQPCTLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14944585 | 0.71 | CYP11B1 (0.40) | CYP11B1CYP11B2BRD4LMNACYP19A1 | |
| SCHEMBL23405844 | 0.70 | CYP11B1 (0.34) | CYP11B1CYP11B2PKM | |
| SCHEMBL28326060 | 0.69 | CYP11B1 (0.69) | CYP11B1CYP11B2BRD4SMN1; SMN2TDP1 | |
| SCHEMBL11484822 | 0.69 | CYP11B1 (0.38) | CYP11B1CYP11B2YTHDC1QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2872515-B1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-08 | — | — | EP | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| WO-2014009509-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CYP11B1 2635/4885ADRA2C 3120/4885CYP11B2 2555/4885 |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CYP11B1 2635/4885ADRA2C 3120/4885CYP11B2 2555/4885 |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CYP11B1 2635/4885ADRA2C 3120/4885CYP11B2 2555/4885 |
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CYP11B1 2635/4885ADRA2C 3120/4885CYP11B2 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.